Payment overview · 2025
General Payments
$328.15
17 reported records · 8 companies
Healthcare provider profile · identity verified
Samir G Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPOTSWOOD, NJ · NPI 1588659296
Verified facts
What the public records show
CMS Open Payments records show Samir G Patel, MD received $328.15 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.36 | 25.1% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $78.99 | 24.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.34 | 17.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.19 | 9.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.26 | 8.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.52 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.99 | 4.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.50 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $249.16 | 16 |
| Education | $78.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.36 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | SANOFI-AVENTIS U.S. LLC | $78.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.34 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
172 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1231 | 336 |
| Amlodipine Besylate | Amlodipine Besylate | 694 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 125 |
| Furosemide | Furosemide | 442 | 111 |
| Metformin Hcl | Metformin Hcl | 423 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 402 | 128 |
| Losartan Potassium | Losartan Potassium | 386 | 114 |
| Lisinopril | Lisinopril | 320 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 99 |
| Glimepiride | Glimepiride | 312 | 78 |
| Eliquis | Apixaban | 302 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 264 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 71 |
| Alprazolam | Alprazolam | 260 | 44 |
| Gabapentin | Gabapentin | 245 | 60 |
| Labetalol Hcl | Labetalol Hcl | 209 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 205 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 107 |
| Simvastatin | Simvastatin | 191 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 50 |
| Carvedilol | Carvedilol | 177 | 44 |
| Nifedipine Er | Nifedipine | 173 | 50 |
| Farxiga | Dapagliflozin Propanediol | 172 | 38 |
| Omeprazole | Omeprazole | 157 | 42 |
| Montelukast Sodium | Montelukast Sodium | 148 | 34 |
| Warfarin Sodium | Warfarin Sodium | 146 | 11 |
| Potassium Chloride | Potassium Chloride | 135 | 33 |
| Famotidine | Famotidine | 128 | 47 |
| Azithromycin | Azithromycin | 118 | 94 |
| Mirtazapine | Mirtazapine | 117 | 28 |
| Divalproex Sodium | Divalproex Sodium | 116 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 44 |
| Meloxicam | Meloxicam | 110 | 42 |
| Ozempic | Semaglutide | 110 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 25 |
| Jardiance | Empagliflozin | 103 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 79 |
| Trazodone Hcl | Trazodone Hcl | 96 | 26 |
| Januvia | Sitagliptin Phosphate | 93 | 15 |
| Clonidine Hcl | Clonidine Hcl | 92 | 23 |
| Allopurinol | Allopurinol | 91 | 23 |
| Entresto | Sacubitril/Valsartan | 91 | 11 |
| Alendronate Sodium | Alendronate Sodium | 80 | 32 |
| Donepezil Hcl | Donepezil Hcl | 79 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 31 |
| Midodrine Hcl | Midodrine Hcl | 76 | 14 |
| Enalapril Maleate | Enalapril Maleate | 74 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 71 | 14 |
| Prednisone | Prednisone | 71 | 49 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 15 |
| Clonazepam | Clonazepam | 63 | 16 |
| Levetiracetam | Levetiracetam | 63 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 12 |
| Risperidone | Risperidone | 59 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 11 |
| Lidocaine | Lidocaine | 57 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 28 |
| Glipizide | Glipizide | 54 | 16 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Repaglinide | Repaglinide | 52 | suppressed |
| Lactulose | Lactulose | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 11 |
| Folic Acid | Folic Acid | 48 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 16 |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 18 |
| Finasteride | Finasteride | 42 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 41 | 37 |
| Retacrit | Epoetin Alfa-Epbx | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Valsartan | Valsartan | 41 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Nateglinide | Nateglinide | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 13 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 11 |
| Naproxen | Naproxen | 29 | 25 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 12 |
| Spironolactone | Spironolactone | 27 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 18 |
| Zonisamide | Zonisamide | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.15 · 17 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, Cologuard Collection Kit, DUPIXENT, FARXIGA, FREESTYLE LIBRE 3, Kerendia, OTEZLA, REPATHA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error